Ocugen to present 12-month Phase 2 ArMaDa results for OCU410 in geographic atrophy at AAO 2026

Phase 2 ArMaDa readouts for OCU410 in geographic atrophy are scheduled for Oct. 9 and Oct. 11, 2026, with management saying the 12-month update covers safety and efficacy outcomes; no metrics were disclosed. Phase 1/2 GARDian1 results for OCU410ST in Stargardt disease will be presented in early October 2026.